{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-24-000026","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.117366+00:00","generated_at":"2026-06-02T05:17:12.877450+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio Q1 net loss $43.9M, cash $370M; Phase 2b data for ANB032 by YE2024, $50M royalty monetization","bullets":["Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.","Cash, cash equivalents, investments total $370.1M (excl. $50M monetization); cash runway through year-end 2026.","Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis enrolling; top-line data expected by year-end 2024.","Phase 2b trial for rosnilimab (PD-1 agonist) in RA and Phase 2 trial in UC enrolling; top-line data mid-2025 and H1 2026.","Announced $50M capped non-recourse royalty monetization from Sagard for additional Jemperli royalties; positive Phase 3 imsidolimab results in GPP."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-24-000026","json":"https://secwatch.observer/filing/0001370053-24-000026.json","markdown":"https://secwatch.observer/filing/0001370053-24-000026.md","text":"https://secwatch.observer/filing/0001370053-24-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/0001370053-24-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/anab-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:17:12.877450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92df3e412a3b328ddf5a4b9c0837e27b9e613615","claim":"ANAPTYSBIO, INC reported first quarter ended March 31, 2024 results: revenue $7.2 million.","evidence_excerpt":"activities as well as a one-time non-operating cash payment of $10.9 million during the quarter. ◦ Reiterating cash runway through year-end 2026 • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023. The change is due primarily to increased royalties","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/0001370053-24-000026-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$7.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}